Results 211 to 220 of about 648,308 (386)

Comparative Bioequivalence and Safety Evaluation of Ibuprofen/Phenylephrine Hydrochloride Fixed‐Dose Combination Tablets in Healthy Chinese Volunteers

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract This single‐center, randomized, open‐label bioequivalence program compared two fixed‐dose combination (FDC) tablets containing ibuprofen (200 mg) and phenylephrine hydrochloride (10 mg) from different manufacturers in healthy Chinese adults under fasting and fed conditions. A three‐period, partially replicated crossover design was used for the
Menghan Ye   +8 more
wiley   +1 more source

Novel Sensitive, Specific and Rapid Pharmacogenomic test for the Prediction of Abacavir Hypersensitivity Reaction: HLA-B*57:01 Detection by Real-Time PCR

open access: green, 2011
Cinzia Dello Russo   +11 more
openalex   +2 more sources

Ladybug Hypersensitivity Among Residents of Homes Infested with Ladybugs in Kentucky [PDF]

open access: bronze, 2006
K. D. Sharma   +3 more
openalex   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee   +5 more
wiley   +1 more source

Metal Allergies in Total Shoulder Arthroplasty: A Scoping Review and Clinical Update. [PDF]

open access: yesJB JS Open Access
Haase LR   +5 more
europepmc   +1 more source

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy